Xenon Pharmaceuticals XENE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's operating cash flow?
- Xenon Pharmaceuticals (XENE) reported operating cash flow of -$88.9M in Q1 2026.
- How has Xenon Pharmaceuticals's operating cash flow changed year-over-year?
- Xenon Pharmaceuticals's operating cash flow decreased by 44.2% year-over-year, from -$61.65M to -$88.9M.
- What is the long-term trend for Xenon Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's operating cash flow has grown at a 41.6% compound annual growth rate (CAGR), from -$69.5M to -$279.12M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.